Geode Capital Management’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-95,656
Closed -$38.3K 4817
2023
Q3
$38.3K Hold
95,656
﹤0.01% 4484
2023
Q2
$66K Hold
95,656
﹤0.01% 4446
2023
Q1
$755K Buy
95,656
+31,460
+49% +$110K ﹤0.01% 3473
2022
Q4
$57K Sell
64,196
-159
-0.2% -$163 ﹤0.01% 4561
2022
Q3
$70K Hold
64,355
﹤0.01% 4689
2022
Q2
$79K Buy
64,355
+6,014
+10% +$8.04K ﹤0.01% 4669
2022
Q1
$137K Sell
58,341
-9
-0% -$21 ﹤0.01% 4538
2021
Q4
$180K Sell
58,350
-25
-0% -$83 ﹤0.01% 4525
2021
Q3
$237K Sell
58,375
-5
-0% -$21 ﹤0.01% 4370
2021
Q2
$282K Sell
58,380
-5,068
-8% -$22.7K ﹤0.01% 4195
2021
Q1
$329K Buy
63,448
+431
+0.7% +$3K ﹤0.01% 3957
2020
Q4
$420K Buy
63,017
+1,574
+3% +$12.9K ﹤0.01% 3640
2020
Q3
$625K Buy
61,443
+18,190
+42% +$214K ﹤0.01% 3368
2020
Q2
$542K Buy
43,253
+29,880
+223% +$418K ﹤0.01% 3348
2020
Q1
$146K Sell
13,373
-2,153
-14% -$14.4K ﹤0.01% 3642
2019
Q4
$81K Hold
15,526
﹤0.01% 4012
2019
Q3
$112K Hold
15,526
﹤0.01% 3924
2019
Q2
$139K Hold
15,526
﹤0.01% 3876
2019
Q1
$152K Hold
15,526
﹤0.01% 3806
2018
Q4
$186K Buy
15,526
+1,802
+13% +$26.2K ﹤0.01% 3700
2018
Q3
$222K Hold
13,724
﹤0.01% 3741
2018
Q2
$498K Buy
13,724
+4,087
+42% +$141K ﹤0.01% 3442
2018
Q1
$300K Hold
9,637
﹤0.01% 3571
2017
Q4
$372K Hold
9,637
﹤0.01% 3467
2017
Q3
$205K Hold
9,637
﹤0.01% 3660
2017
Q2
$193K Buy
9,637
+1,104
+13% +$22.8K ﹤0.01% 3701
2017
Q1
$190K Buy
+8,533
New +$134K ﹤0.01% 3675

Other funds holding BLPH

Geode Capital Management's BLPH Position: Q4 2023 in Review

Geode Capital Management sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q4 2023, closing a stake of 95,656 shares — an estimated $38.3K sold.

Geode Capital Management first reported a position in BLPH in Q1 2017 and held it in 27 quarters. The position peaked at $755K in Q1 2023. 2 funds tracked by Wall St. Rank hold BLPH as of Q4 2023.

  • Geode Capital Management reported no remaining Bellerophon Therapeutics, Inc. position as of Q4 2023 after selling out during the quarter.
  • Geode Capital Management sold 95,656 Bellerophon Therapeutics, Inc. shares in Q4 2023, an estimated $38.3K.
  • Geode Capital Management first reported a position in Bellerophon Therapeutics, Inc. in Q1 2017 and held it in 27 quarters.
  • Geode Capital Management's Bellerophon Therapeutics, Inc. position peaked at $755K in Q1 2023.
  • 2 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q4 2023.

Based on Geode Capital Management's 13F filing for Q4 2023, filed 13 Feb 2024.